G

    GlucoTrack Inc (GCTK)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $4.25
    +3.97 (+1407.09%)

    Market Cap: $225,080

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    		$-0.76N/AN/ABeat+96.1%
    Sep 25
    		$-4.64$0.00N/AMiss+99.6%
    Jun 25
    		$-9.62N/AN/ABeat+99.0%
    Mar 25
    		$-40.35N/AN/ABeat+94.3%
    Dec 24
    		$-19.51N/AN/ABeat+97.2%
    Sep 24
    		$-1091.07N/AN/ABeat-87.9%
    Jun 24
    		$-983.76N/AN/ABeat-200.6%
    Mar 24
    		$-703.61N/AN/ABeat-41.4%
    Dec 23
    		$-692.70N/AN/ABeat-865773.6%
    Sep 23
    		$-580.70N/AN/ABeat-967740.3%
    Jun 23
    		$-327.25N/AN/ABeat-467400.6%
    Mar 23
    		$-497.69N/AN/ABeat-710885.4%
    Dec 22
    		$-0.08N/AN/ABeat+20.0%
    Sep 22
    		$-0.06N/AN/ABeat-20.0%
    Jun 22
    		$-0.07N/AN/ABeat+90.3%
    Mar 22
    		$-0.07N/AN/ABeat-600.0%
    Dec 21
    		$-0.10N/AN/ABeat+100.0%
    Sep 21
    		$-0.05N/AN/ABeat-51.5%
    Jun 21
    		$-0.72N/AN/ABeat-1835.5%
    Mar 21
    		$-0.01N/AN/ABeat+81.0%
    Dec 20
    		$-341.49N/AN/ABeat-19.0%
    Sep 20
    		$-0.03N/AN/ABeat-230.0%
    Jun 20
    		$-0.04N/AN/ABeat-272.0%
    Mar 20
    		$-0.05N/AN/ABeat+98.3%
    Dec 19
    		$-286.86N/AN/ABeat+98.4%
    Sep 19
    		$-0.01N/AN/ABeat+96.8%
    Jun 19
    		$-0.01N/AN/ABeat+97.0%
    Mar 19
    		$-3.13N/AN/ABeat-820.6%
    Dec 18
    		$-17848.62N/AN/ABeat-3797479.0%
    Sep 18
    		$-0.31N/AN/ABeat+29.5%
    Jun 18
    		$-0.33N/AN/ABeat+31.2%
    Mar 18
    		$-0.34N/AN/ABeat+29.2%
    Dec 17
    		$-0.47N/AN/ABeat+100.0%
    Sep 17
    		$-0.44N/AN/ABeat+100.0%
    Jun 17
    		$-0.48N/AN/ABeat-
    Mar 17
    		$-0.48N/AN/ABeat-
    Dec 16
    		$-18307.47N/AN/ABeat-
    Sep 16
    		$-23016.90N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.01EV/EBITDA-1.02x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-621.00%ROIC-6319.21%
    Financial Health
    Debt/Equity-1.11xInterest CoverageN/A
    Current Ratio0.46xQuick Ratio0.46x
    Trading Statistics
    Beta0.66Avg Volume5.02M
    52-Week High$14.1452-Week Low$0.25

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.72
    SMA 20$0.57
    SMA 50$0.46
    SMA 200$1.83
    EMA 10$1.04
    EMA 20$0.73
    EMA 50$0.58
    EMA 200$2.27

    MACD

    Line: 0.28Signal: 0.04Hist: 0.24

    ADX

    ADX: 36.0+DI: 87.4-DI: 3.3

    Aroon & PSAR

    Aroon Up100.0
    Aroon Down8.0
    PSAR$0.28

    Bollinger Bands

    Upper Band$2.31
    Lower Band$-1.17
    %B Position60728%(Upper)
    Band Width1.56

    RSI (14-Day)

    Overbought
    93.9

    Momentum Oscillators

    Stoch %K33.9
    Stoch %D15.7
    Williams %R-2.7
    ROC (10d)1142.7%
    Momentum3.91
    CCI (20d)663.1
    MFI (14d)16.3

    Volatility Measures

    ATR (14d)$0.35(8.3%)
    StdDev (20d)0.87
    Hist Vol5003.2%(High)

    Volume Flow

    VWAP$4.20
    OBV570.2M
    AD Line288.7B
    CMF (20d)-0.219

    Volume Metrics

    Avg Vol (20d)5.1M
    Vol Ratio0.0x(Low)
    VWMA (20d)$0.50

    Pivot Points

    R3$0.30
    R2$0.29
    R1$0.29
    Pivot Point$0.28
    S1$0.28
    S2$0.27
    S3$0.27

    Advanced Oscillators

    TSI44.68
    Ultimate Osc91.0
    KST714.38

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$24,000$0$0$0$42,000$0
    Cost of Revenue$0$0$14,000$0$0$0$14,000$0$0$0$21,000$0
    Gross Profit$0$0$-14,000$0$0$0$-14,000$0$0$0$21,000$0
    Operating Expenses$3.40M$4.20M$3.49M$4.31M$4.80M$3.50M$3.85M$3.25M$4.49M$2.95M$2.42M$2.22M
    R&D$2.02M$2.13M$1.63M$3.17M$3.15M$1.87M$1.70M$2.06M$3.59M$2.15M$1.74M$1.69M
    SG&A$1.38M$2.07M$2.29M$1.02M$1.65M$1.63M$2.45M$1.06M$802,000$733,000$553,000$531,000
    Operating Income$-3,400,000$-4,203,000$-3,487,000$-4,309,000$-4,796,000$-3,498,000$-3,854,000$-3,251,000$-4,491,000$-2,951,000$-2,417,000$-2,224,000
    Interest Income$0$0$0$2,000$29,000$0$0$-1,848,000$2,000$0$0$0
    Interest Expense$414,000$131,000$141,000$0$0$3.33M$6.22M$1.84M$0$0$2,000$0
    Income Before Tax$-3,814,000$-4,334,000$-3,628,000$-4,171,000$-4,756,000$-6,833,000$-10,070,000$-5,087,000$-4,489,000$-2,951,000$-2,419,000$-2,223,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-3,814,000$-4,334,000$-3,628,000$-4,171,000$-4,756,000$-6,833,000$-10,094,000$-5,087,000$-4,489,000$-2,927,000$-2,412,000$-2,223,000
    EBITDA$-3,643,000$-4,164,000$-3,437,000$-4,133,000$-4,772,000$-6,822,000$-11,604,000$-2,899,000$-4,483,000$-2,947,000$-2,427,000$-2,209,000
    EBIT$-3,814,000$-4,334,000$-3,597,000$-4,173,000$-4,785,000$-6,833,000$-11,916,000$-3,239,000$-4,491,000$-2,951,000$-2,419,000$-2,223,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about GCTK

    News

    Lōkahi plans one shot per visit instead of 15 for honeybee-venom treatment

    Lōkahi Therapeutics, a subsidiary of Glucotrack, has initiated GMP manufacturing for its lead development candidate, LT-100 (pure honeybee venom), intended for osteoarthritis pain. This move signifies a strategic shift from 15 intradermal injections per treatment to a single subcutaneous injection per visit, aiming for a more patient-friendly approach. The company expects to enroll the first patient for clinical trials later this year, pending successful manufacturing and regulatory reviews.

    Stock Titan•8/25/26•
    Bullish

    Form 8K GlucoTrack Inc For: 19 August By Investing.com

    This article reports on GlucoTrack Inc.'s Form 8K filing for August 19, 2026. The filing is a standard SEC disclosure for significant corporate events. The piece provides the document's publication details from Investing.com.

    Investing.com South Africa•8/19/26•
    Neutral

    Form 8K GlucoTrack Inc For: 19 August By Investing.com

    This article announces the filing of a Form 8K by GlucoTrack Inc. on August 19. It provides no further details on the content of the filing but lists the company's stock symbol GCTK and its current performance. The rest of the page consists of financial market data, news headlines, and navigational elements.

    Investing.com Nigeria•8/19/26•
    Neutral

    Glucotrack shareholders approve director elections, reverse split, and warrant inducement

    Glucotrack (NASDAQ:GCTK) shareholders have approved several key proposals at their 2026 annual meeting, including the election of six directors, the 2025 executive compensation plan, and the appointment of CBIZ CPAs P.C. as their independent accounting firm. Significant approvals include a reverse stock split not exceeding one-for-thirty to address the stock's substantial decline, and a warrant inducement proposal involving repricing existing warrants and issuing new ones. These actions follow recent strategic moves such as a business combination with Lōkahi Therapeutics and securing bridge financing, alongside a patent allowance for their continuous glucose monitoring system.

    Investing.com•8/19/26•
    Somewhat-Bearish

    Glucotrack shareholders approve director elections, reverse split, and warrant inducement

    Glucotrack shareholders have approved key proposals at their 2026 annual meeting, including the election of six directors, the 2025 executive compensation plan, and the appointment of CBIZ CPAs P.C. They also approved a reverse stock split to address the stock's significant decline and a warrant inducement proposal. These decisions follow the company's recent business combination with Lōkahi Therapeutics and a new patent for its continuous glucose monitoring system.

    Investing.com•8/19/26•
    Somewhat-Bearish

    Frequently Asked Questions About GCTK

    Does GCTK pay dividends?
    GlucoTrack Inc (GCTK) does not currently pay a regular dividend.
    What is GCTK's market cap?
    GlucoTrack Inc (GCTK) has a market capitalization of $225,080 with a current stock price of $4.25.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In